Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ucb S.A. (OP: UCBJF )

128.50 -0.22 (-0.17%)
Streaming Delayed Price Updated: 11:14 AM EDT, Apr 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 128.50
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 128.72
Today's Range 128.50 - 128.50
52wk Range 69.70 - 128.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target
Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of... 
Via Benzinga
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga

Performance

YTD
+28.50%
+28.50%
1 Month
+7.17%
+7.17%
3 Month
+28.50%
+28.50%
6 Month
+67.24%
+67.24%
1 Year
+34.48%
+34.48%

More News

Read More
Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts
Via Benzinga
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
Via Benzinga
Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path
Via Benzinga
UCB's Rare Childhood Epilepsy Drug Scores FDA Approval
Via Benzinga
Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane
Via Benzinga
UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study
Via Benzinga
UCB to Buy Epilepsy-Focused Zogenix In $1.9B Deal: See The Highlights
Via Benzinga
UCB Gets EU Approval For Bimekizumab In Psoriasis
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.